DOC Updates

With over 200,000 hospital admissions each year from diabetic ketoacidosis, new continuous ketone monitoring systems can address a critical care gap. In the second part of our special series, Neil Skolnik explores the value of this new technology and delves into specific case studies.
This special episode is sponsored with support from Abbott.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Heath Sciences, Boston, Mass.; Clinical pharmacist and the Clinical Director of Cardiometabolic Services at Well Life Medical in Peabody, MA
References:
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care 2024;47:1257–1275 doi.org/10.2337/dci24-0032
Continuous ketone monitoring: Exciting implications for clinical practice. Diabetes Obesity, and Metabolism. 2024; 26 (Suppl. 7): 47-58. doi.org/10.1111/dom.15921
Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology. The Lancet Diabetes & Endocrinology. 2026; 14:82 doi.org/10.1016/S2213-8587(25)00331-6

There are multiple options now for slowing the progression of chronic kidney disease. In part 5 of our special series, host Dr. Neil Skolnik takes a case-based approach to explore treatment options for CKD.
This special episode is sponsored with support from Bayer.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Holly Kramer, MD, MPH, Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University in Chicago, Illinois
Selected References:
Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 doi.org/10.2337/dc26-S011
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 doi.org/10.1056/NEJMoa2025845
Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 doi.org/10.1056/NEJMoa2024816
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121 doi.org/10.1056/NEJMoa2403347
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023;46(9):1574–1586 doi.org/10.2337/dci23-0030
The Kidney Failure Risk Equation - kidneyfailurerisk.com

Welcome to the latest episode (November 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.
This month on DOC Updates:
Oser, et al. Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes. New England Journal of Medicine. October 2026; doi.org/10.1056/NEJMoa2608571
Islet autoantibody screening identifies early-stage type 1 diabetes across Europe, Need-To-Know Institute press release
Yang, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis. JAMA. Published online October 2026. doi.org/10.1001/jama.2026.19921
Jastreboff, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. September, 2026. doi.org/10.1056/NEJMoa2604169
Bellido, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Volume 408, Issue 10563. doi.org/10.1016/S0140-6736(26)01861-1
Colhoun, et al. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. European Heart Journal. 2026; ehag524, doi.org/10.1093/eurheartj/ehag524
Garvey, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology, 2026; 14, 914-926. doi.org/10.1016/S2213-8587(26)00213-5
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health
DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice.
For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

We are entering an era of choice in terms of diabetes and obesity therapies. Choice is good, but having a keen understanding of each medication is crucial to avoid being overwhelmed. In this special episode of DOC Updates, host Dr. Neil Skolnik explores the latest amylin-based therapies.
This special episode is sponsored with support from Novo Nordisk.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science
Selected References:
Garvey, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity," N Engl J Med 2025;393:635-647 doi.org/10.1056/NEJMoa2502081
Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study," The Lancet Diabetes & Endocrinology, 2026; 14, 649-661 doi.org/10.1016/S2213-8587(26)00126-9

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts.
2:20 Our hosts speak with Klara Klein, MD, PhD, assistant professor of medicine at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, and Marie Claire Abram, attending physician at Maine Health Medical Center in Portland, Maine. Their article, "Variability in Autoantibody Ordering Patterns Suggests Potential for Diabetes Misclassification," is available at doi.org/10.2337/doc26-0071.
13:10 Next, Jane introduces Miranda Zuniga-Kennedy, MS, a clinical psychology graduate student at WSU. Her article, "Determinants of Cognitive Change Over 1 Year in Older Adults With Type 1 Diabetes," is available at doi.org/10.2337/doc26-0069.
25:05 Finally, Richard and Jane highlight some of their favorite articles from the September-October issue.
Chae, et al. "Physical Activity Patterns in Adults Taking Glucagon-Like Peptide-1 Receptor Agonists: An All of Us Cross-Sectional Study," doi.org/10.2337/doc26-0062

Descarpentrie, et al. "School Meal Participation, Overall Dietary Intake, and Prediabetes Prevalence Among U.S. Adolescents: Insights From the National Health and Nutrition Examination Survey (2017–2023)," doi.org/10.2337/doc26-0084

Bannuru, et al. "Comparative Effectiveness of Continuous Glucose Monitoring Versus Blood Glucose Monitoring in Pregnancy With Diabetes: Systematic Review and Meta-analysis With Trial Sequential Analysis," doi.org/10.2337/doc26-0018

March, et al. "Implementation of Diabetes Care Coordination in Schools Across Pediatric Centers in the T1D Exchange Quality Improvement Collaborative," doi.org/10.2337/doc26-0110

Adel, et al. "Virtual Diabetes Optimization Program (VDOP) for Veterans With Uncontrolled Diabetes," doi.org/10.2337/doc26-0020

Smith-Morris, et al. "Culinary Medicine and Medical Nutrition Therapy Interventions to Improve Glycemic Control in Type 2 Diabetes: A Pragmatic Trial During the COVID-19 Pandemic," doi.org/10.2337/doc26-0048

To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.